# Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

> **NCT05372887** · PHASE2 · WITHDRAWN · sponsor: **Tonix Pharmaceuticals, Inc.**

## Conditions studied

- PTSD

## Interventions

- **DRUG:** TNX-102 SL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05372887
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-14
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was stopped due to business reasons.
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372887, "Safety and Efficacy Study of TNX-102 SL in Participants With PTSD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05372887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*